A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab

Arthritis, Rheumatoid Clinical Trial

Official title:

A Single Center, Single Dose, Open-label Study in Healthy Japanese Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Otilimab

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05304130
• Other study ID #: 208326
• Status: Withdrawn
• Phase: Phase 1
• Start date: February 8, 2023
• Est. completion date: May 4, 2023

Study information

• Verified date: January 2023
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) profiles of otilimab in healthy Japanese participants.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 4, 2023
• Est. primary completion date: May 4, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 50 Years

Eligibility

Inclusion criteria:

• Participant must be 20 to 50 years of age inclusive, at the time of signing the informed consent.
• Japanese participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
• A Coronavirus Disease-2019 (COVID-19) screening with negative test: Two consecutive approved molecular tests (Polymerase chain reaction [PCR] or antigen test) separated by greater than (>)24 hours. The second test should be within 72 hours of admission to the unit on Day -1.
• Body mass index (BMI) within the range 18.5 to 24.9 kilograms per meter square (kg/m^2) (inclusive).

Exclusion Criteria:

• History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatment; or interfering with the interpretation of data.
• Active infections (including localized infections), or history of recurrent infections (excluding recurrent fungal infections of the nail bed), or has required management of acute or chronic infections
• History of any respiratory disease which (in the opinion of the investigator) would compromise participant safety or the ability of the participant to complete the study.
• Clinically-significant or unstable (in the opinion of the investigator) persistent cough or dyspnea that is unexplained.
• Current or previous active Tuberculosis (TB), history of untreated or incompletely treated active or latent TB, suspected or known extra pulmonary TB.
• Previous close contact with a person with active TB and did not receive satisfactory anti-tuberculosis treatment as per World Health Organization (WHO) or national guidelines.
• Hemoglobin less than or equal to (<=)9 grams per deciliter (g/dL); white blood cell (WBC) count <=3.0 times 10^9/ Liter (L); platelet count <=100 times 10^9/L; absolute neutrophil count (ANC) <=1.0 times 10^9/L; lymphocyte count <=0.75 times 10^9/L at screening.
• A vaccination (live or attenuated) within 30 days prior to Day 1 or Bacillus Calmette-Guerin (BCG) vaccination within 365 days prior to Day 1, or a live vaccination planned during the course of the study. Any COVID-19 vaccination within 14 days prior to enrolment.
• Any surgical procedure, including bone or joint surgery/synovectomy within 8 weeks prior to Day 1 or any planned surgery within the duration of the study.
• Significant allergies to humanized Monoclonal antibody (mAb).
• Participants with known COVID-19 positive contacts within 14 days prior to screening.
• History of lymphoma, leukemia, or any malignancy.
• History of infected joint prosthesis at any time, with the prosthesis still in situ. History of leg ulcers, catheters, chronic sinusitis or recurrent chest or urinary tract infections.
• Use of prescription or non-prescription drugs within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) before the start of study intervention until completion of the evaluation visit, unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study.
• Treatment with biologic agents (such as mAb including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.
• Blood donation/sampling within 60 days prior to screening.
• The participant with positive Serological test for syphilis, Human immunodeficiency virus (HIV) antigen/antibody, or Human T-cell lymphotropic virus type 1 (HTLV-1) antibody.
• The participant with positive test for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), Hepatitis B surface antibody (HBsAb), or Hepatitis C virus (HCV) antibody.
• Positive pre-study drug/alcohol screen.
• Participants with signs and symptoms suggestive of COVID-19 (fever, cough) within 14 days prior inpatient admission on Day -1.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid

Intervention

Biological:
• Otilimab
Otilimab will be administered via pre-filled syringe.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum drug concentration (Cmax) following administration of otilimab		Up to 8 Weeks
Primary	Area under the concentration-time curve from pre-dose to infinity (AUC[0-infinity]) following administration of otilimab		Up to 8 Weeks
Secondary	Area under the plasma concentration-time curve from pre-dose to t (AUC[0-t]) following administration of otilimab		Up to 8 Weeks
Secondary	Time to maximum plasma concentration (Tmax) following administration of otilimab		Up to 8 Weeks
Secondary	Elimination half-life (t1/2) following administration of otilimab		Up to 8 Weeks
Secondary	Time to reach the last quantifiable plasma concentration (Tlast) following administration of otilimab		Up to 8 Weeks
Secondary	Number of participants with Adverse events (AEs), Serious adverse events (SAEs) and Adverse events of special interests (AESIs)		Up to 8 weeks
Secondary	Change from Baseline in hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count (Giga cells per liter)		Baseline and up to 8 weeks
Secondary	Change from Baseline in hematology parameter: Red blood cell (RBC) count (Trillion cells per liter)		Baseline and up to 8 weeks
Secondary	Change from Baseline in hematology parameter: Hemoglobin (Grams per Liter)		Baseline and up to 8 weeks
Secondary	Change from Baseline in hematology parameter: Hematocrit (Proportion of red blood cells in blood)		Baseline and up to 8 weeks
Secondary	Change from Baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters)		Baseline and up to 8 weeks
Secondary	Change from Baseline in hematology parameter: Mean corpuscular hemoglobin (MCH) (Picograms)		Baseline and up to 8 weeks
Secondary	Change from Baseline in hematology parameter: Percentage of reticulocytes (Percentage of reticulocytes)		Baseline and up to 8 weeks
Secondary	Change from Baseline in clinical chemistry parameters: Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Aspartate aminotransferase (AST), Creatine kinase, Gamma Glutamyl transferase (GGT), Lactate Dehydrogenase (International units per Liter)		Baseline and up to 8 weeks
Secondary	Change from Baseline in clinical chemistry parameters: Calcium, glucose, potassium, sodium, Chloride, Phosphate and Blood urea nitrogen (BUN) (Millimoles per Liter)		Baseline and up to 8 weeks
Secondary	Change from Baseline in clinical chemistry parameters: Creatinine, direct bilirubin, total bilirubin and uric acid (Micromoles per liter)		Baseline and up to 8 weeks
Secondary	Change from Baseline in clinical chemistry parameters: Albumin and Total protein (Grams per liter)		Baseline and up to 8 weeks
Secondary	Change from Baseline in clinical chemistry parameter: C-reactive protein (CRP) (Milligrams per liter		Baseline and up to 8 weeks
Secondary	Change from Baseline in clinical chemistry parameter: Amylase (Units per liter)		Baseline and up to 8 weeks
Secondary	Change from Baseline in lipid panel parameters: Total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides (Millimoles per Liter)		Baseline and up to 8 weeks
Secondary	Number of participants with abnormal urinalysis parameters by Dipstick Method		Baseline and up to 8 weeks
Secondary	Change from Baseline in vital signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) (Millimeters of mercury)		Baseline and up to 8 weeks
Secondary	Change from Baseline in vital sign: Pulse rate (Beats per minute)		Baseline and up to 8 weeks
Secondary	Change from Baseline in vital signs: Body temperature (Degrees Celsius)		Baseline and up to 8 weeks
Secondary	Change from Baseline in Electrocardiogram (ECG) parameters: PR interval, QRS duration, QT interval and corrected QT (QTc) interval (Milliseconds)		Baseline and up to 8 weeks
Secondary	Number of participants with anti-drug antibodies (ADAs) to otilimab		Up to Week 8
Secondary	Number of participants with drug-neutralizing antibodies to otilimab		Up to Week 8